Shares of other companies:
A.O. Smith: Great Company, Inferior Investment
May 18, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ABBV Stock News and Mentions of AbbVie Inc. Stocktwits
Updated: May 20, 2024 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where AbbVie Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of AbbVie Inc. (ABBV).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the AbbVie stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of AbbVie Inc. (ABBV)
May 18, 2024 (14:19) / "Business Insider" (by Nicolás Jose Rodriguez)
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...
In Article Trend: Somewhat-Bullish
May 18, 2024 (14:19) / "Benzinga" (by Nicolás Jose Rodriguez)
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...
In Article Trend: Somewhat-Bullish
May 17, 2024 (18:12) / "Business Insider" (by Vandana Singh)
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald has initiated coverage on AbbVie Inc ( NYSE:ABBV ) , a global pharma company. The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.
In Article Trend: Somewhat-Bullish
May 17, 2024 (17:47) / "Benzinga" (by Vandana Singh)
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst - AbbVie ( NYSE:ABBV ) , Bristol-Myers Squibb ( NYSE:BMY )
Cantor Fitzgerald has initiated coverage on AbbVie Inc ABBV, a global pharma company. The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.
In Article Trend: Somewhat-Bullish
May 17, 2024 (12:30) / "Kiplinger" (by Matthew Housiaux)
The Fight Against Cancer Enters a New Phase
To help you understand what is going on in the health sector our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts ( Get a free issue of The Kiplinger Letter or subscribe ) .
In Article Trend: Neutral
May 17, 2024 (11:12) / "Benzinga" (by Globe Newswire)
INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process - Cerevel Therapeutics Hldg ( NASDAQ:CERE )
NEW YORK, May 17, 2024 ( GLOBE NEWSWIRE ) -- If you invested in Cerevel Therapeutics Holdings, Inc. CERE you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below.
In Article Trend: Somewhat-Bullish
)
May 17, 2024 (05:24) / "Business Standard" (by Press Trust of India)
Pharma major Glenmark gets USFDA nod for generic ophthalmic solution
Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions.
In Article Trend: Somewhat-Bullish
May 17, 2024 (05:11) / "The Financial Express" (by Health Desk)
Glenmark Pharmaceuticals gets USFDA approval for its drug to treat glaucoma
Glenmark Pharmaceuticals Ltd. on Friday announced that it has received final approval from the United States Food & Drug Administration ( U.S. FDA ) for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%.
In Article Trend: Somewhat-Bullish
May 16, 2024 (20:15) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 16, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 ...
In Article Trend: Somewhat-Bullish
May 16, 2024 (16:30) / "Benzinga" (by Benzinga Insights)
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today - AbbVie ( NYSE:ABBV )
AbbVie ABBV has outperformed the market over the past 5 years by 1.96% on an annualized basis producing an average annual return of 15.08%. Currently, AbbVie has a market capitalization of $288.26 billion.
In Article Trend: Somewhat-Bullish
May 16, 2024 (15:45) / "Zacks Commentary" (by Zacks Equity Research)
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
May 16, 2024 (13:27) / "Business Insider" (by Mikhaila Friel)
Kristin Chenoweth defends Ariana Grande over rumors that she was dating her 'Wicked' costar
Kristin Chenoweth defends Ariana Grande over 'Wicked' costar rumors - Business Insider ...
In Article Trend: Neutral
May 16, 2024 (12:51) / "Benzinga" (by Upwallstreet)
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game - Pfizer ( NYSE:PFE )
On Sunday, Pfizer PFE and AstraZeneca Plc AZN were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year's "Choose France" business summit.
In Article Trend: Neutral
May 16, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer - Ventyx Biosciences ( NASDAQ:VTYX )
SAN DIEGO, May 16, 2024 ( GLOBE NEWSWIRE ) -- Ventyx Biosciences, Inc. VTYX, ( "Ventyx" ) , a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of ...
In Article Trend: Somewhat-Bullish
May 14, 2024 (17:32) / "Benzinga" (by Nicolás Jose Rodriguez)
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals ( NASDAQ:CRBP ) , AbbVie ( NYSE:ABBV )
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational.
In Article Trend: Somewhat-Bullish
May 14, 2024 (17:31) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in AbbVie - AbbVie ( NYSE:ABBV )
Deep-pocketed investors have adopted a bearish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
May 14, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Boosts Neuropsychiatric Portfolio With New Deal
AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.
In Article Trend: Somewhat-Bullish
May 14, 2024 (14:02) / "GlobeNewswire" (by Genmab A/S)
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association ( EHA ) Congress
Media ReleaseCOPENHAGEN, Denmark. May ...
In Article Trend: Neutral
May 14, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search AbbVie Inc. ( ABBV ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
May 14, 2024 (13:00) / "Benzinga" (by Faith Ashmore)
BioRestorative Therapies ( NASDAQ: BRTX ) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market - AbbVie ( NYSE:ABBV ) , BioRestorative Therapies ( NASDAQ:BRTX )
As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to reach a value of $232.49 billion by 2032, growing at a CAGR of 13.34% between 2024 and 2032.
In Article Trend: Bullish
May 14, 2024 (10:30) / "Motley Fool" (by and David Jagielski)
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors.
In Article Trend: Somewhat-Bullish
May 13, 2024 (22:14) / "Benzinga" (by Globe Newswire)
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
Washington, D.C., May 13, 2024 ( GLOBE NEWSWIRE ) -- Today the U.S. Court of Appeals for the Second Circuit unanimously upheld a district court decision dismissing the In re Bystolic antitrust lawsuit over reverse payments.
In Article Trend: Neutral
May 13, 2024 (15:09) / "Motley Fool" (by James Brumley)
What Is the Dividend Payout for AbbVie Stock?
The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well.
In Article Trend: Neutral
May 13, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
May 13, 2024 (12:39) / "PR Newswire" (by AbbVie)
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next ... PR ...
In Article Trend: Somewhat-Bullish
May 13, 2024 (12:15) / "GlobeNewswire" (by Royalty Pharma plc)
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in the following upcoming investor conferences during the month of May: ...
In Article Trend: Somewhat-Bullish
May 13, 2024 (12:15) / "Benzinga" (by Globe Newswire)
Royalty Pharma to Present at Upcoming Investor Conferences - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, May 13, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ET
In Article Trend: Somewhat-Bullish
May 12, 2024 (18:07) / "PR Newswire" (by Piramal Pharma Ltd)
Piramal Pharma Limited annonce ses résultats pour le quatrième trimestre et l'exercice 2024
MUMBAI, Inde, 12 mai 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , une entreprise pharmaceutique de premier plan à l'échelle mondiale, a dévoilé ses résultats autonomes et consolidés pour le quatrième trimestre ( T4 ) et l'exercice complet se terminant le 31 ...
In Article Trend: Neutral
May 12, 2024 (17:57) / "PR Newswire" (by Piramal Pharma Ltd)
Piramal Pharma Limited gibt Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 bekannt
MUMBAI, Indien, 12. Mai 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , ein weltweit führendes Pharmaunternehmen, gab heute seine Einzel- und Konzernergebnisse für das vierte Quartal ( Q4 ) und das Gesamtjahr ( GJ ) bis 31. März 2024 bekannt.
In Article Trend: Somewhat-Bearish
May 11, 2024 (20:09) / "Benzinga" (by Globe Newswire)
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LABP, DOMA, FXNC - First Ntl ( NASDAQ:FXNC ) , Doma Holdings ( NYSE:DOMA )
NEW YORK, May 11, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Landos Biopharma, Inc.
In Article Trend: Somewhat-Bullish
May 11, 2024 (12:38) / "Motley Fool" (by Mark Roussin)
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends.
In Article Trend: Bullish
May 11, 2024 (07:50) / "Motley Fool" (by Justin Pope)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future.
In Article Trend: Somewhat-Bullish
May 10, 2024 (19:15) / "Benzinga" (by Benzinga Insights)
( ABBV ) - Analyzing AbbVie's Short Interest - AbbVie ( NYSE:ABBV )
AbbVie's ABBV short percent of float has risen 4.05% since its last report. The company recently reported that it has 13.54 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their ...
In Article Trend: Somewhat-Bullish
May 10, 2024 (17:51) / "PR Newswire" (by Piramal Pharma Ltd)
Piramal Pharma Limited Announces Results for Q4 and FY2024
MUMBAI, India, May 10, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter ( Q4 ) and Full Year ( FY ) ended 31st March 2024. • Revenue from ...
In Article Trend: Bullish
May 10, 2024 (17:45) / "Canada Newswire" (by Piramal Pharma Ltd)
Piramal Pharma Limited Announces Results for Q4 and FY2024
MUMBAI, India, May 10, 2024 /CNW/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter ( Q4 ) and Full Year ( FY ) ended 31st March 2024. • Revenue from Operations ...
In Article Trend: Bullish
May 10, 2024 (15:18) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
In Article Trend: Neutral
May 10, 2024 (15:16) / "Zacks Commentary" (by Zacks Equity Research)
Ironwood ( IRWD ) Q1 Earnings & Revenues Fall Shy of Estimates
Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.
In Article Trend: Neutral
May 10, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
CollPlant Biotechnologies ( CLGN ) Soars 8.2%: Is Further Upside Left in the Stock?
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
In Article Trend: Somewhat-Bullish
May 10, 2024 (13:30) / "Motley Fool" (by David Jagielski)
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
These are low-risk stocks with high yields.
In Article Trend: Somewhat-Bullish
May 9, 2024 (15:51) / "Investors Business Daily" (by Investor's Business Daily)
How This IBD 50 Stock Is Stacking Up Wins In 2024, And Outperforming Peers
Neurocrine Biosciences Is Making Good On Its Ingrezza Diversification, And Its Biotech Stock Is Flying Investor's Business Daily ...
In Article Trend: Neutral
May 9, 2024 (11:30) / "Benzinga" (by Globe Newswire)
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan - Coherus BioSciences ( NASDAQ:CHRS )
- New $38.7 million term loan with a May 2029 maturity - - $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® -
In Article Trend: Neutral
May 9, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Royalty Pharma Reports First Quarter 2024 Results - Royalty Pharma ( NASDAQ:RPRX )
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 million Commitment to grow dividend by mid-single digit percentage annually
In Article Trend: Somewhat-Bullish
May 9, 2024 (10:45) / "GlobeNewswire" (by Royalty Pharma plc)
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab
NEW YORK, May 09, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. ( ImmuNext ) for approximately $525 million in cash including estimated transaction costs.
In Article Trend: Somewhat-Bullish
May 9, 2024 (10:45) / "Benzinga" (by Globe Newswire)
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab - Royalty Pharma ( NASDAQ:RPRX )
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma's development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (20:10) / "Benzinga" (by Globe Newswire)
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX )
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 ( EGFRxCD3 T-cell engager ) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first ...
In Article Trend: Neutral
May 8, 2024 (18:00) / "Motley Fool" (by Motley Fool Transcribing)
Teva Pharmaceutical Industries ( TEVA ) Q1 2024 Earnings Call Transcript
TEVA earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
May 8, 2024 (17:40) / "Stocknews.com" (by Defense World Staff)
Agilysys ( NASDAQ:AGYS ) Upgraded at StockNews.com
StockNews.com upgraded shares of Agilysys ( NASDAQ:AGYS - Free Report ) from a hold rating to a buy rating in a research note published on Tuesday. Separately, Needham & Company LLC boosted their price objective on shares of Agilysys from $92.00 to $100.00 and gave the stock a buy rating in a ...
In Article Trend: Bullish
May 8, 2024 (15:13) / "Stocknews.com" (by Defense World Staff)
Bausch Health Companies ( NYSE:BHC ) Downgraded to "Hold" at StockNews.com
StockNews.com cut shares of Bausch Health Companies ( NYSE:BHC - Free Report ) from a buy rating to a hold rating in a research note published on Tuesday morning. Other research analysts also recently issued research reports about the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (13:59) / "Stocknews.com" (by Defense World Staff)
Apple Hospitality REIT ( NYSE:APLE ) Lifted to Hold at StockNews.com
StockNews.com upgraded shares of Apple Hospitality REIT ( NYSE:APLE - Free Report ) from a sell rating to a hold rating in a research report released on Tuesday morning.
In Article Trend: Somewhat-Bullish
May 8, 2024 (12:58) / "Stocknews.com" (by Defense World Staff)
Boise Cascade ( NYSE:BCC ) Upgraded by StockNews.com to "Buy"
StockNews.com upgraded shares of Boise Cascade ( NYSE:BCC - Free Report ) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. Other research analysts have also recently issued reports about the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
BOSTON, May 08, 2024 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (11:40) / "Stocknews.com" (by Defense World Staff)
Assertio ( NASDAQ:ASRT ) Rating Increased to Buy at StockNews.com
StockNews.com upgraded shares of Assertio ( NASDAQ:ASRT - Free Report ) from a hold rating to a buy rating in a research report report published on Tuesday morning. Shares of ASRT stock opened at $1.11 on Tuesday. The company has a current ratio of 1.83, a quick ratio of 1.43 and a ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (10:40) / "Stocknews.com" (by Defense World Staff)
StockNews.com Downgrades IES ( NASDAQ:IESC ) to Buy
StockNews.com lowered shares of IES ( NASDAQ:IESC - Free Report ) from a strong-buy rating to a buy rating in a research report released on Tuesday. Shares of NASDAQ:IESC opened at $170.96 on Tuesday. The business has a fifty day simple moving average of $121.55 and a 200 day simple moving ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (09:30) / "Stocknews.com" (by Defense World Staff)
CASI Pharmaceuticals ( NASDAQ:CASI ) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on shares of CASI Pharmaceuticals ( NASDAQ:CASI - Free Report ) in a research report sent to investors on Tuesday. The firm issued a hold rating on the biotechnology company's stock. Shares of CASI opened at $2.66 on Tuesday.
In Article Trend: Neutral
May 8, 2024 (09:30) / "Stocknews.com" (by Defense World Staff)
Alico ( NASDAQ:ALCO ) Lifted to Hold at StockNews.com
StockNews.com upgraded shares of Alico ( NASDAQ:ALCO - Free Report ) from a sell rating to a hold rating in a research report report published on Tuesday morning. Shares of NASDAQ ALCO opened at $26.02 on Tuesday. The stock has a fifty day moving average price of $28.10 and a 200 day moving ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (09:30) / "Stocknews.com" (by Defense World Staff)
Air Transport Services Group ( NASDAQ:ATSG ) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded shares of Air Transport Services Group ( NASDAQ:ATSG - Free Report ) from a sell rating to a hold rating in a report issued on Tuesday morning. Other equities research analysts have also issued reports about the company.
In Article Trend: Somewhat-Bullish
May 8, 2024 (09:30) / "Stocknews.com" (by Defense World Staff)
A-Mark Precious Metals ( NASDAQ:AMRK ) Stock Rating Lowered by StockNews.com
StockNews.com downgraded shares of A-Mark Precious Metals ( NASDAQ:AMRK - Free Report ) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
In Article Trend: Somewhat-Bullish
May 8, 2024 (09:26) / "Stocknews.com" (by Defense World Staff)
Werner Enterprises ( NASDAQ:WERN ) Downgraded to Sell at StockNews.com
StockNews.com cut shares of Werner Enterprises ( NASDAQ:WERN - Free Report ) from a hold rating to a sell rating in a report issued on Tuesday. A number of other brokerages also recently weighed in on WERN. Robert W.
In Article Trend: Somewhat-Bullish
May 8, 2024 (08:13) / "Stocknews.com" (by Defense World Staff)
StockNews.com Upgrades OneSpan ( NASDAQ:OSPN ) to Buy
OneSpan ( NASDAQ:OSPN - Get Free Report ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Monday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Calithera Biosciences ( NASDAQ:CALA ) Now Covered by StockNews.com
Analysts at StockNews.com started coverage on shares of Calithera Biosciences ( NASDAQ:CALA - Get Free Report ) in a report issued on Wednesday. The firm set a "hold" rating on the biotechnology company's stock. Shares of NASDAQ CALA opened at $0.02 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
CB Financial Services ( NASDAQ:CBFV ) Earns Hold Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of CB Financial Services ( NASDAQ:CBFV - Get Free Report ) in a report issued on Wednesday. The brokerage set a "hold" rating on the bank's stock. CBFV has been the topic of a number of other reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Calumet Specialty Products Partners ( NASDAQ:CLMT ) Earns Hold Rating from Analysts at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Calumet Specialty Products Partners ( NASDAQ:CLMT - Get Free Report ) in a research note issued on Wednesday. The brokerage set a "hold" rating on the oil and gas company's stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Cinedigm ( NASDAQ:CIDM ) Coverage Initiated at StockNews.com
Equities researchers at StockNews.com began coverage on shares of Cinedigm ( NASDAQ:CIDM - Get Free Report ) in a research report issued on Wednesday. The brokerage set a "hold" rating on the stock. Shares of CIDM opened at $0.83 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Consolidated Communications ( NASDAQ:CNSL ) Now Covered by StockNews.com
Research analysts at StockNews.com began coverage on shares of Consolidated Communications ( NASDAQ:CNSL - Get Free Report ) in a report issued on Wednesday. The brokerage set a "sell" rating on the utilities provider's stock. Shares of Consolidated Communications stock opened at $4.27 on ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
StockNews.com Downgrades Flexsteel Industries ( NASDAQ:FLXS ) to Hold
Flexsteel Industries ( NASDAQ:FLXS - Get Free Report ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Wednesday. Separately, TheStreet raised Flexsteel Industries from a "c" rating to a "b-" rating in a research ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
First Capital ( NASDAQ:FCAP ) Receives New Coverage from Analysts at StockNews.com
Investment analysts at StockNews.com began coverage on shares of First Capital ( NASDAQ:FCAP - Get Free Report ) in a report released on Wednesday. The firm set a "hold" rating on the savings and loans company's stock. FCAP opened at $28.03 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
StockNews.com Initiates Coverage on SB Financial Group ( NASDAQ:SBFG )
StockNews.com initiated coverage on shares of SB Financial Group ( NASDAQ:SBFG - Get Free Report ) in a research note issued to investors on Wednesday. The firm set a "hold" rating on the financial services provider's stock. NASDAQ:SBFG opened at $13.51 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Conduent ( NASDAQ:CNDT ) Upgraded by StockNews.com to "Buy"
Conduent ( NASDAQ:CNDT - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Wednesday. Separately, Noble Financial began coverage on Conduent in a research report on Thursday, March 14th.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Paramount Global ( NASDAQ:PARA ) Lifted to "Hold" at StockNews.com
Paramount Global ( NASDAQ:PARA - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report released on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
QUALCOMM ( NASDAQ:QCOM ) Rating Lowered to Buy at StockNews.com
QUALCOMM ( NASDAQ:QCOM - Get Free Report ) was downgraded by research analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued on Wednesday. QCOM has been the subject of several other reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Mesoblast ( NASDAQ:MESO ) Downgraded by StockNews.com
Mesoblast ( NASDAQ:MESO - Get Free Report ) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday. Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
StockNews.com Initiates Coverage on SP Plus ( NASDAQ:SP )
Research analysts at StockNews.com assumed coverage on shares of SP Plus ( NASDAQ:SP - Get Free Report ) in a research report issued on Wednesday. The firm set a "hold" rating on the business services provider's stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
NXP Semiconductors ( NASDAQ:NXPI ) Upgraded at StockNews.com
NXP Semiconductors ( NASDAQ:NXPI - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Wednesday. Other analysts have also recently issued research reports about the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Intuit ( NASDAQ:INTU ) Downgraded by StockNews.com
Intuit ( NASDAQ:INTU - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
StockNews.com Begins Coverage on Jaguar Health ( NASDAQ:JAGX )
Analysts at StockNews.com assumed coverage on shares of Jaguar Health ( NASDAQ:JAGX - Get Free Report ) in a research note issued to investors on Wednesday. The brokerage set a "sell" rating on the biotechnology company's stock. Shares of NASDAQ:JAGX opened at $0.30 on Wednesday.
In Article Trend: Neutral
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Trevena ( NASDAQ:TRVN ) Research Coverage Started at StockNews.com
Stock analysts at StockNews.com initiated coverage on shares of Trevena ( NASDAQ:TRVN - Get Free Report ) in a research report issued to clients and investors on Wednesday. The firm set a "sell" rating on the biopharmaceutical company's stock.
In Article Trend: Neutral
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
CapStar Financial ( NASDAQ:CSTR ) Receives New Coverage from Analysts at StockNews.com
StockNews.com began coverage on shares of CapStar Financial ( NASDAQ:CSTR - Get Free Report ) in a report issued on Wednesday. The firm set a "hold" rating on the bank's stock. CapStar Financial stock opened at $20.10 on Wednesday. CapStar Financial has a 52 week low of $11.22 and a 52 week ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Airgain ( NASDAQ:AIRG ) Earns Hold Rating from Analysts at StockNews.com
Analysts at StockNews.com initiated coverage on shares of Airgain ( NASDAQ:AIRG - Get Free Report ) in a report issued on Wednesday. The brokerage set a "hold" rating on the technology company's stock. NASDAQ:AIRG opened at $5.46 on Wednesday. Airgain has a 52 week low of $1.63 and a 52 week ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
Rubicon Technology ( NASDAQ:RBCN ) Coverage Initiated at StockNews.com
Stock analysts at StockNews.com started coverage on shares of Rubicon Technology ( NASDAQ:RBCN - Get Free Report ) in a research note issued to investors on Wednesday. The brokerage set a "sell" rating on the semiconductor company's stock. Shares of NASDAQ:RBCN opened at $0.82 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
ACNB ( NASDAQ:ACNB ) Downgraded to "Sell" at StockNews.com
ACNB ( NASDAQ:ACNB - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Wednesday. Separately, Piper Sandler reduced their price objective on ACNB from $40.00 to $37.00 and set a "neutral" rating on the ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Ambac Financial Group ( NYSE:AMBC ) Upgraded at StockNews.com
Ambac Financial Group ( NYSE:AMBC - Get Free Report ) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Wednesday. AMBC stock opened at $18.04 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Aeterna Zentaris ( NASDAQ:AEZS ) Coverage Initiated at StockNews.com
Analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris ( NASDAQ:AEZS - Get Free Report ) ( TSE:AEZ ) in a research note issued to investors on Wednesday. The firm set a "sell" rating on the biopharmaceutical company's stock. Aeterna Zentaris stock opened at $8.03 on ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
TE Connectivity ( NYSE:TEL ) Coverage Initiated at StockNews.com
Analysts at StockNews.com initiated coverage on shares of TE Connectivity ( NYSE:TEL - Get Free Report ) in a note issued to investors on Wednesday. The firm set a "buy" rating on the electronics maker's stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Snowflake ( NYSE:SNOW ) Downgraded by StockNews.com
Snowflake ( NYSE:SNOW - Get Free Report ) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Wednesday. Other analysts also recently issued research reports about the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
StockNews.com Initiates Coverage on L.S. Starrett ( NYSE:SCX )
StockNews.com began coverage on shares of L.S. Starrett ( NYSE:SCX - Get Free Report ) in a report issued on Wednesday. The firm set a "buy" rating on the stock. Shares of SCX stock opened at $16.08 on Wednesday. The company has a current ratio of 3.11, a quick ratio of 1.42 and a ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Enservco ( NYSEAMERICAN:ENSV ) Now Covered by StockNews.com
Research analysts at StockNews.com initiated coverage on shares of Enservco ( NYSEAMERICAN:ENSV - Get Free Report ) in a research report issued to clients and investors on Wednesday. The firm set a "sell" rating on the oil and gas producer's stock. ENSV stock opened at $0.21 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Birks Group ( NYSEAMERICAN:BGI ) Earns Sell Rating from Analysts at StockNews.com
Investment analysts at StockNews.com began coverage on shares of Birks Group ( NYSEAMERICAN:BGI - Get Free Report ) in a note issued to investors on Wednesday. The firm set a "sell" rating on the stock. BGI opened at $2.57 on Wednesday. Birks Group has a 12 month low of $2.25 and a 12 month ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Enerplus ( NYSE:ERF ) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com started coverage on shares of Enerplus ( NYSE:ERF - Get Free Report ) ( TSE:ERF ) in a research report issued on Wednesday. The brokerage set a "hold" rating on the oil and natural gas company's stock. ERF has been the subject of several other research ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Lear ( NYSE:LEA ) Downgraded by StockNews.com
Lear ( NYSE:LEA - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a report released on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Avalon ( NYSE:AWX ) Coverage Initiated by Analysts at StockNews.com
Research analysts at StockNews.com assumed coverage on shares of Avalon ( NYSE:AWX - Get Free Report ) in a note issued to investors on Wednesday. The firm set a "hold" rating on the stock. NYSE AWX opened at $2.13 on Wednesday.
In Article Trend: Neutral
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Can-Fite BioPharma ( NYSE:CANF ) Receives New Coverage from Analysts at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma ( NYSE:CANF - Get Free Report ) in a report released on Wednesday. The brokerage set a "hold" rating on the stock. Shares of NYSE:CANF opened at $2.07 on Wednesday.
In Article Trend: Neutral
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Civeo ( NYSE:CVEO ) Lifted to "Strong-Buy" at StockNews.com
Civeo ( NYSE:CVEO - Get Free Report ) was upgraded by research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report released on Wednesday. Separately, Stifel Nicolaus upped their price target on Civeo from $30.00 to $31.00 and gave the company a "buy" rating in a ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
InnSuites Hospitality Trust ( NYSE:IHT ) Research Coverage Started at StockNews.com
Investment analysts at StockNews.com began coverage on shares of InnSuites Hospitality Trust ( NYSE:IHT - Get Free Report ) in a report released on Wednesday. The brokerage set a "hold" rating on the stock. IHT stock opened at $1.34 on Wednesday.
In Article Trend: Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Cummins ( NYSE:CMI ) Raised to Buy at StockNews.com
Cummins ( NYSE:CMI - Get Free Report ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Wednesday. CMI has been the subject of several other research reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Credit Suisse Group ( NYSE:CS ) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com started coverage on shares of Credit Suisse Group ( NYSE:CS - Get Free Report ) in a report issued on Wednesday. The brokerage set a "hold" rating on the financial services provider's stock. NYSE:CS opened at $0.89 on Wednesday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:34) / "Stocknews.com" (by Defense World Staff)
Comstock ( NYSE:LODE ) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of Comstock ( NYSE:LODE - Get Free Report ) in a report released on Wednesday. The firm set a "sell" rating on the stock. Shares of LODE stock opened at $0.25 on Wednesday. Comstock has a fifty-two week low of $0.24 and a fifty-two week high of $0.99.
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:32) / "Stocknews.com" (by Defense World Staff)
El Pollo Loco ( NASDAQ:LOCO ) Stock Rating Upgraded by StockNews.com
El Pollo Loco ( NASDAQ:LOCO - Get Free Report ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a report issued on Monday. Separately, Truist Financial boosted their price objective on El Pollo Loco from $10.00 to $12.00 and gave the company a "hold" rating ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (07:16) / "Stocknews.com" (by Defense World Staff)
British American Tobacco ( NYSE:BTI ) Stock Rating Lowered by StockNews.com
British American Tobacco ( NYSE:BTI - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Monday. Shares of BTI opened at $29.95 on Monday. British American Tobacco has a 1 year low of $28.25 and a 1 year ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
BorgWarner ( NYSE:BWA ) Lifted to "Buy" at StockNews.com
BorgWarner ( NYSE:BWA - Get Free Report ) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Monday. A number of other equities analysts have also recently weighed in on the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
Forum Energy Technologies ( NYSE:FET ) Lowered to "Hold" at StockNews.com
Forum Energy Technologies ( NYSE:FET - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Monday. Separately, TheStreet cut Forum Energy Technologies from a "c" rating to a "d" rating in a research note on ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
Hyatt Hotels ( NYSE:H ) Upgraded by StockNews.com to "Hold"
Hyatt Hotels ( NYSE:H - Get Free Report ) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Monday. H has been the subject of several other research reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
Welltower ( NYSE:WELL ) Upgraded to "Hold" at StockNews.com
Welltower ( NYSE:WELL - Get Free Report ) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Monday. Other analysts have also recently issued reports about the company.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
Manchester United ( NYSE:MANU ) Upgraded at StockNews.com
Manchester United ( NYSE:MANU - Get Free Report ) was upgraded by analysts at StockNews.com to a "sell" rating in a research report issued on Monday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
StockNews.com Lowers Kohl's ( NYSE:KSS ) to Hold
Kohl's ( NYSE:KSS - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Monday. KSS has been the subject of a number of other research reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
AG Mortgage Investment Trust ( NYSE:MITT ) Stock Rating Upgraded by StockNews.com
AG Mortgage Investment Trust ( NYSE:MITT - Get Free Report ) was upgraded by investment analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Monday. Other research analysts have also issued research reports about the stock.
In Article Trend: Bullish
May 8, 2024 (06:32) / "Stocknews.com" (by Defense World Staff)
Phillips 66 ( NYSE:PSX ) Rating Lowered to Hold at StockNews.com
Phillips 66 ( NYSE:PSX - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Monday. Other research analysts have also recently issued reports about the company.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:31) / "Stocknews.com" (by Defense World Staff)
Ryman Hospitality Properties ( NYSE:RHP ) Stock Rating Lowered by StockNews.com
Ryman Hospitality Properties ( NYSE:RHP - Get Free Report ) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Monday. RHP has been the topic of a number of other reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:31) / "Stocknews.com" (by Defense World Staff)
Banco Santander ( NYSE:SAN ) Stock Rating Upgraded by StockNews.com
Banco Santander ( NYSE:SAN - Get Free Report ) was upgraded by research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a note issued to investors on Monday. Separately, Barclays raised shares of Banco Santander from an "equal weight" rating to an "overweight" rating ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
U.S. Silica ( NYSE:SLCA ) Now Covered by StockNews.com
Analysts at StockNews.com assumed coverage on shares of U.S. Silica ( NYSE:SLCA - Get Free Report ) in a research note issued on Monday. The firm set a "hold" rating on the mining company's stock. Separately, Citigroup lifted their price target on U.S.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Summit Midstream Partners ( NYSE:SMLP ) Rating Increased to Strong-Buy at StockNews.com
Summit Midstream Partners ( NYSE:SMLP - Get Free Report ) was upgraded by research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research report issued on Monday. SMLP opened at $35.00 on Monday. Summit Midstream Partners has a twelve month low of $13.00 and a ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Aldeyra Therapeutics ( NASDAQ:ALDX ) Stock Rating Lowered by StockNews.com
Aldeyra Therapeutics ( NASDAQ:ALDX - Get Free Report ) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Monday.
In Article Trend: Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
AMERISAFE ( NASDAQ:AMSF ) Rating Lowered to Sell at StockNews.com
AMERISAFE ( NASDAQ:AMSF - Get Free Report ) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating in a report issued on Monday. Several other research analysts also recently commented on the company.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
AxoGen ( NASDAQ:AXGN ) Rating Lowered to Hold at StockNews.com
AxoGen ( NASDAQ:AXGN - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Monday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
DMC Global ( NASDAQ:BOOM ) Stock Rating Lowered by StockNews.com
DMC Global ( NASDAQ:BOOM - Get Free Report ) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Monday. Separately, Stifel Nicolaus cut their price objective on shares of DMC Global from $27.00 to $24.00 and set a "buy" ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
AXT ( NASDAQ:AXTI ) Rating Increased to Hold at StockNews.com
AXT ( NASDAQ:AXTI - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Monday. Several other analysts have also recently weighed in on the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Beacon Roofing Supply ( NASDAQ:BECN ) Rating Lowered to Hold at StockNews.com
Beacon Roofing Supply ( NASDAQ:BECN - Get Free Report ) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Monday. Several other equities research analysts have also commented on BECN. Robert W.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
StockNews.com Downgrades Dorchester Minerals ( NASDAQ:DMLP ) to Hold
Dorchester Minerals ( NASDAQ:DMLP - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Monday. DMLP opened at $31.94 on Monday. The stock has a fifty day moving average of $33.09 and a 200-day ...
In Article Trend: Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Columbia Banking System ( NASDAQ:COLB ) Stock Rating Upgraded by StockNews.com
Columbia Banking System ( NASDAQ:COLB - Get Free Report ) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued on Monday. COLB has been the subject of several other reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Cimpress ( NASDAQ:CMPR ) Rating Lowered to Buy at StockNews.com
Cimpress ( NASDAQ:CMPR - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Monday. CMPR has been the subject of a number of other reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
StockNews.com Downgrades Identiv ( NASDAQ:INVE ) to Sell
Identiv ( NASDAQ:INVE - Get Free Report ) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Monday. Separately, B.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Insmed ( NASDAQ:INSM ) Rating Lowered to Sell at StockNews.com
Insmed ( NASDAQ:INSM - Get Free Report ) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Monday. Other research analysts have also issued research reports about the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Investors Title ( NASDAQ:ITIC ) Rating Increased to Buy at StockNews.com
Investors Title ( NASDAQ:ITIC - Get Free Report ) was upgraded by stock analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Monday. Separately, TheStreet raised Investors Title from a "c+" rating to a "b-" rating in a report on Wednesday, ...
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Joint ( NASDAQ:JYNT ) Rating Increased to Buy at StockNews.com
Joint ( NASDAQ:JYNT - Get Free Report ) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Monday. JYNT has been the subject of a number of other reports. B.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
Lamar Advertising ( NASDAQ:LAMR ) Stock Rating Lowered by StockNews.com
Lamar Advertising ( NASDAQ:LAMR - Get Free Report ) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a report released on Monday. Other equities analysts have also issued research reports about the stock.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:30) / "Stocknews.com" (by Defense World Staff)
StockNews.com Downgrades Malibu Boats ( NASDAQ:MBUU ) to Sell
Malibu Boats ( NASDAQ:MBUU - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Monday. MBUU has been the subject of a number of other research reports.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:12) / "Stocknews.com" (by Defense World Staff)
Alamo Group ( NYSE:ALG ) Lowered to Hold at StockNews.com
Alamo Group ( NYSE:ALG - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Monday.
In Article Trend: Somewhat-Bullish
May 8, 2024 (06:12) / "Stocknews.com" (by Defense World Staff)
Adecoagro ( NYSE:AGRO ) Rating Increased to Buy at StockNews.com
Adecoagro ( NYSE:AGRO - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Monday. Shares of AGRO stock opened at $11.28 on Monday. The stock has a fifty day moving average of $10.75 and a 200 day ...
In Article Trend: Bullish
May 8, 2024 (06:12) / "Stocknews.com" (by Defense World Staff)
ACCO Brands ( NYSE:ACCO ) Downgraded by StockNews.com to Hold
ACCO Brands ( NYSE:ACCO - Get Free Report ) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a report released on Monday. Separately, Barrington Research reiterated an "outperform" rating and set a $7.50 price objective on shares of ACCO Brands in ...
In Article Trend: Somewhat-Bullish
May 7, 2024 (20:30) / "Barrons" (by Josh Nathan-Kazis)
Teva Stock Is Powering Ahead as Schizophrenia News Offsets Mixed Earnings
Teva Earnings Are Wednesday. Here's What to Expect. ...
In Article Trend: Neutral
May 7, 2024 (20:15) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® ( pembrolizumab )
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform ...
In Article Trend: Neutral
May 7, 2024 (20:01) / "PR Newswire" (by Inc.)
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million
In Article Trend: Somewhat-Bullish
May 7, 2024 (11:10) / "GlobeNewswire" (by BioPorto A/S)
BioPorto A/S Appoints President and CEO of BioPorto Inc.
May 7, 2024News release ...
In Article Trend: Somewhat-Bullish
May 6, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
May 6, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc. - Pacific Software ( OTC:PFSF )
DANA POINT, Calif., May 06, 2024 ( GLOBE NEWSWIRE ) -- Pacific Software Inc. ( "PFSF" ) acquired certain assets of Dreamaderm Inc. ( "Dreamaderm" ) through a Plan of Acquisition, dated January 24, 2024. PFSF will now be the exclusive holder of a patented, first-in-class cosmeceutical asset, ...
In Article Trend: Somewhat-Bullish
May 6, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should First Trust Morningstar Dividend Leaders ETF ( FDL ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
May 5, 2024 (17:44) / "Motley Fool" (by Prosper Junior Bakiny)
3 Reasons to Buy AbbVie Stock on the Dip
A little patience with the drugmaker should pay off.
In Article Trend: Somewhat-Bullish
May 3, 2024 (20:00) / "Benzinga" (by Zacks)
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA ( NYSE:FIX ) , AbbVie ( NYSE:ABBV )
The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this week. J&J JNJ announced a new plan to completely resolve its talc-related lawsuits.
In Article Trend: Neutral
May 3, 2024 (15:29) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
In Article Trend: Neutral
May 3, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Somewhat-Bullish
May 2, 2024 (18:30) / "Benzinga" (by Benzinga Insights)
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today - AbbVie ( NYSE:ABBV )
AbbVie ABBV has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%. Currently, AbbVie has a market capitalization of $282.47 billion.
In Article Trend: Somewhat-Bullish
May 2, 2024 (15:01) / "GlobeNewswire" (by Genmab A/S)
Genmab Announces Financial Results for the First Quarter of 2024
May 2, 2024 Copenhagen, Denmark. Interim Report for the First Quarter Ended March ...
In Article Trend: Somewhat-Bullish
May 2, 2024 (13:15) / "GlobeNewswire" (by Aprea Therapeutics)
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation ...
In Article Trend: Neutral
May 2, 2024 (13:15) / "Benzinga" (by Globe Newswire)
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Aprea Therapeutics ( NASDAQ:APRE )
DOYLESTOWN, Pa., May 02, 2024 ( GLOBE NEWSWIRE ) -- Aprea Therapeutics, Inc. APRE ( "Aprea", or the "Company" ) , a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q.
In Article Trend: Neutral
May 1, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why AbbVie Inc. ( ABBV ) is a Trending Stock
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
May 1, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Bullish
May 1, 2024 (12:40) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.
In Article Trend: Somewhat-Bullish
May 1, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree U.S. Quality Dividend Growth ETF ( DGRW ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 30, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight
The medical dynamometers market is predicted to surge owing to the rise in bone-related conditions like osteoporosis and arthritis, along with an uptick in sports injuries and the expanding elderly demographic.
In Article Trend: Bullish
April 30, 2024 (20:49) / "Associated Press" (by MATTHEW PERRONE)
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON ( AP ) - Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest effort by the Biden administration targeting pharmaceutical that drive up prices.
In Article Trend: Neutral
April 30, 2024 (15:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
April 30, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
In Article Trend: Somewhat-Bullish
April 30, 2024 (13:59) / "StockMarket.com" (by Joe Samuel)
2 Dividend Stocks To Watch In May 2024
The stock market is where investors trade shares of publicly traded companies. Among various investment options, dividend stocks are popular for their potential to provide income through regular dividend payments.
In Article Trend: Somewhat-Bullish
April 30, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
In Article Trend: Somewhat-Bullish
April 30, 2024 (12:00) / "PR Newswire" (by LLC)
Genstar Names Keith Martino to Strategic Advisory Board
Experienced Pharma Executive to Advise on the Firm's Healthcare Investments
In Article Trend: Somewhat-Bullish
April 30, 2024 (08:00) / "GlobeNewswire" (by Alvotech)
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® ( adalimumab )
REYKJAVIK, ICELAND, PARSIPPANY, N.J., and TEL AVIV, ISRAEL ( April 30, 2024 ) - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...
In Article Trend: Somewhat-Bullish
April 30, 2024 (08:00) / "GlobeNewswire" (by Alvotech)
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® ( adalimumab )
REYKJAVIK, Iceland and PARSIPPANY, N.J. and TEL AVIV, Israel, April 30, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of ...
In Article Trend: Somewhat-Bullish
April 29, 2024 (16:27) / "Investors Business Daily" (by Investor's Business Daily)
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'
AbbVie Stock: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales Investor's Business Daily ...
In Article Trend: Neutral
April 28, 2024 (08:20) / "Motley Fool" (by Prosper Junior Bakiny)
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either.
In Article Trend: Somewhat-Bullish
April 27, 2024 (11:15) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks.
In Article Trend: Somewhat-Bullish
April 26, 2024 (20:07) / "Motley Fool" (by James Brumley)
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Investors are struggling to see past the end of Humira's dominance.
In Article Trend: Somewhat-Bullish
April 26, 2024 (19:15) / "Motley Fool" (by Motley Fool Transcribing)
AbbVie ( ABBV ) Q1 2024 Earnings Call Transcript
ABBV earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 26, 2024 (18:41) / "Benzinga" (by Vandana Singh)
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost - Cigna Group ( NYSE:CI )
On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Evernorth is a subsidiary of The Cigna Group CI.
In Article Trend: Somewhat-Bullish
April 26, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Beats on Q1 Earnings & Sales, Ups '24 EPS View
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
In Article Trend: Neutral
April 26, 2024 (14:53) / "Zacks Commentary" (by Zacks Equity Research)
PCE/Core PCE Numbers Came In Line With Expectations
Pre-market futures are sunnier this morning. After seeing shadows in economic data related to the dreaded "stagflation" dynamic, Personal Income Expenditures ( PCE ) numbers for March look to have assuaged a bit of those fears this morning.
In Article Trend: Neutral
April 26, 2024 (14:33) / "Zacks Commentary" (by Mark Vickery)
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
In Article Trend: Neutral
April 26, 2024 (14:00) / "Investors Business Daily" (by Investor's Business Daily)
CPAP Stock Rockets As Quarterly Report Wipes Out Weight-Loss Woes
ResMed Stock Hits 8-Month High After Quarterly Beat Wipes Out Weight-Loss Drug Woes Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (13:54) / "Benzinga" (by Vandana Singh)
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook - Landos Biopharma ( NASDAQ:LABP ) , AbbVie ( NYSE:ABBV )
Friday, AbbVie Inc ABBV reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis.
In Article Trend: Somewhat-Bullish
April 26, 2024 (13:03) / "Investors Business Daily" (by Investor's Business Daily)
AbbVie Beats Quarterly Views As Skyrizi Nearly Snags Humira's Title
AbbVie Stock: AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Beats Q1 Earnings and Revenue Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 26, 2024 (11:35) / "PR Newswire" (by AbbVie)
AbbVie Reports First-Quarter 2024 Financial Results
NORTH CHICAGO, Ill., April 26, 2024 /PRNewswire/ -- AbbVie ( NYSE:ABBV ) announced financial results for the first quarter ended March 31, 2024. "We continue to demonstrate outstanding operational execution and delivered another quarter of strong results," said Richard A.
In Article Trend: Neutral
April 26, 2024 (10:48) / "Benzinga" (by Shanthi Rexaline)
MSFT, GOOGL Earnings Lift Nasdaq, S&P 500 Futures - But Can They Beat Inflation? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Tech earnings could come to the market's rescue as traders remain jittery about the outcome of key inflation data due on Friday. AI giants Alphabet, Inc. GOOGL GOOG and Microsoft Corp. MSFT set a positive tone for tech companies with strong performances in the first quarter.
In Article Trend: Neutral
April 25, 2024 (20:45) / "PR Newswire" (by Inc.)
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( "Halozyme" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
In Article Trend: Somewhat-Bullish
April 25, 2024 (17:58) / "Benzinga" (by Vandana Singh)
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study - AbbVie ( NYSE:ABBV ) , Regeneron Pharmaceuticals ( NASDAQ:REGN )
Thursday, AbbVie Inc ABBV released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib ( Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response ) versus dupilumab ( Dupixent, per its labeled dose ) for ...
In Article Trend: Neutral
April 25, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
In Article Trend: Somewhat-Bullish
April 24, 2024 (16:05) / "Zacks Commentary" (by Sweta Killa)
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
In Article Trend: Neutral
April 24, 2024 (14:09) / "Zacks Commentary" (by Kinjel Shah)
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
In Article Trend: Somewhat-Bullish
April 24, 2024 (14:02) / "GlobeNewswire" (by Inc.)
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( Coherus, Nasdaq: CHRS ) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 ...
In Article Trend: Neutral
April 24, 2024 (13:19) / "Zacks Commentary" (by Ahan Chakraborty)
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
In Article Trend: Somewhat-Bullish
April 24, 2024 (12:30) / "CNBC" (by Dave Sheaff Gilreath)
Op-ed: Here are 6 health-care stocks to watch now, amid a bumpy recovery
Health care, long an ailing stock market sector, has recovered over the past six months, with currently robust vital signs and strong growth projections.
In Article Trend: Somewhat-Bullish
April 24, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Invesco Pharmaceuticals ETF ( PJP ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (19:24) / "CNN" (by Jacqueline Howard)
CDC issues health advisory about risks of counterfeit or mishandled Botox injections
The US Centers for Disease Control and Prevention issued an advisory Tuesday about the risks of counterfeit or mishandled Botox injections after dangerous fake versions of the product have been found in several states.
In Article Trend: Neutral
April 23, 2024 (18:45) / "Benzinga" (by Benzinga Insights)
AbbVie's Options Frenzy: What You Need to Know - AbbVie ( NYSE:ABBV )
Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 15 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 46% ...
In Article Trend: Neutral
April 23, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly ( LLY ) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 23, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Gear Up for AbbVie ( ABBV ) Q1 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
In Article Trend: Neutral
April 23, 2024 (12:00) / "PR Newswire" (by Congruence Therapeutics)
Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer
-Mr. Taffy joins from Schrödinger, bringing a wealth of relevant expertise to Congruence-
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:00) / "Canada Newswire" (by Congruence Therapeutics)
Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer
-Mr. Taffy joins from Schrödinger, bringing a wealth of relevant expertise to Congruence-
In Article Trend: Somewhat-Bullish
April 23, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should Pacer US Cash Cows 100 ETF ( COWZ ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (21:33) / "Benzinga" (by Globe Newswire)
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
In Article Trend: Somewhat-Bullish
April 22, 2024 (16:56) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
In Article Trend: Somewhat-Bullish
April 22, 2024 (15:09) / "Benzinga" (by Globe Newswire)
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 ( GLOBE NEWSWIRE ) -- Anthos Therapeutics, Inc. ( Anthos ) , is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences ( BXLS ) , today announced the appointment of Bill Meury as CEO and member of ...
In Article Trend: Neutral
April 22, 2024 (13:47) / "Motley Fool" (by Mark Roussin)
Buying the Dip in These 3 Undervalued Dividend Stocks
All three of these stocks look intriguing.
In Article Trend: Bullish
April 22, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Neutral
April 22, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Pacer US Cash Cows 100 ETF ( COWZ ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (08:29) / "Barrons" (by Joe Woelfel)
Nvidia, Tesla, Super Micro, Verizon, Informatica, Coinbase, Cardinal Health, and More Stock Market Movers
Nvidia, Tesla, Super Micro, Salesforce, Verizon, and More Stock Market Movers ...
In Article Trend: Neutral
April 21, 2024 (21:45) / "Benzinga" (by Shanthi Rexaline)
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .
In Article Trend: Neutral
April 20, 2024 (07:44) / "Motley Fool" (by Matt DiLallo)
Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income
The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream.
In Article Trend: Bullish
April 19, 2024 (20:04) / "GlobeNewswire" (by NurExone Biologic Inc)
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (20:04) / "Benzinga" (by Globe Newswire)
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
TORONTO and HAIFA, Israel, April 19, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc.
In Article Trend: Somewhat-Bullish
April 19, 2024 (16:43) / "Investors Business Daily" (by ALLISON GATLIN)
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie Stock Is 10% Off Its Record High, And There's Bad News Heading Into Its First-Quarter Report Investor's Business Daily ...
In Article Trend: Neutral
April 19, 2024 (15:12) / "GlobeNewswire" (by Molecular Partners)
Life Science Cares Launches in Switzerland
First international chapter of Life Science Cares established in Switzerland - bringing hearts and minds together by empowering the life sciences industry to support local communities First international chapter of Life Science Cares established in Switzerland - bringing hearts and minds ...
In Article Trend: Neutral
April 19, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Earnings Preview: AbbVie ( ABBV ) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 19, 2024 (13:15) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
In Article Trend: Neutral
April 19, 2024 (12:15) / "GlobeNewswire" (by Royalty Pharma plc)
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, April 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
In Article Trend: Neutral
April 19, 2024 (12:15) / "Benzinga" (by Globe Newswire)
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, April 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.
In Article Trend: Somewhat-Bullish
April 19, 2024 (10:10) / "GlobeNewswire" (by Alvotech)
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® ( adalimumab )
Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S.
In Article Trend: Somewhat-Bullish
April 19, 2024 (10:10) / "GlobeNewswire" (by Alvotech)
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® ( adalimumab )
REYKJAVIK, Iceland, April 19, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (17:44) / "Benzinga" (by Vandana Singh)
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study - Cerevel Therapeutics Hldg ( NASDAQ:CERE )
On Thursday, Cerevel Therapeutics Holdings Inc. CERE released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa ( LD ) in adults.
In Article Trend: Somewhat-Bullish
April 18, 2024 (10:30) / "GlobeNewswire" (by Cerevel Therapeutics)
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks ...
In Article Trend: Neutral
April 17, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
In Article Trend: Neutral
April 17, 2024 (18:42) / "Benzinga" (by Vandana Singh)
Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions - AbbVie ( NYSE:ABBV )
On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc's ABBV Botox used for cosmetic purposes.
In Article Trend: Neutral
April 17, 2024 (18:00) / "Benzinga" (by Benzinga Insights)
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today - AbbVie ( NYSE:ABBV )
AbbVie ABBV has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $290.03 billion.
In Article Trend: Somewhat-Bullish
April 17, 2024 (13:50) / "Benzinga" (by Globe Newswire)
Continuous Manufacturing Market Size is expected to reach USD 1,420.95 million by 2031, growing at a CAGR of 12.2%: Straits Research
New York, United States, April 17, 2024 ( GLOBE NEWSWIRE ) -- Continuous manufacturing is distinguished from batch manufacturing, which entails production execution in discrete steps separated by intervals by the uninterrupted feeding of raw materials into a manufacturing system and the ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (12:15) / "GlobeNewswire" (by Royalty Pharma plc)
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, April 17, 2024 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.
In Article Trend: Somewhat-Bullish
April 16, 2024 (21:30) / "GlobeNewswire" (by Alvotech)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ ( ustekinumab-aekn ) , biosimilar to Stelara® ( ustekinumab )
REYKJAVIK, Iceland and PARSIPPANY, N.J., April 16, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved ...
In Article Trend: Neutral
April 16, 2024 (21:30) / "GlobeNewswire" (by Alvotech)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ ( ustekinumab-aekn ) , biosimilar to Stelara® ( ustekinumab )
REYKJAVIK, ICELAND & PARSIPPANY, NJ - Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ( ustekinumab-aekn ) injection for ...
In Article Trend: Neutral
April 16, 2024 (20:33) / "CNN" (by Jacqueline Howard)
Counterfeit Botox has been found in several states. Here's what consumers should know.
The US Food and Drug Administration is warning that dangerous counterfeit versions of Botox have been identified in multiple states, putting the safety of consumers at risk.
In Article Trend: Neutral
April 16, 2024 (20:09) / "Forbes" (by Arianna Johnson)
FDA And CDC Launch Investigation Into Counterfeit Botox: What To Know
What To Know About Counterfeit Botox Forbes ...
In Article Trend: Neutral
April 16, 2024 (18:25) / "Benzinga" (by Vandana Singh)
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades - Avalo Therapeutics ( NASDAQ:AVTX )
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc AVTX, noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa ( HS ) and additional updates.
In Article Trend: Somewhat-Bullish
April 16, 2024 (16:00) / "GlobeNewswire" (by OSE Immunotherapeutics)
OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 - OSE Immunotherapeutics SA ( ISIN: FR0012127173.
In Article Trend: Neutral
April 16, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie Inc. ( ABBV ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
April 16, 2024 (11:30) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Q1 Earnings Top Estimates
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.65% and 0.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 15, 2024 (17:31) / "Benzinga" (by Benzinga Insights)
AbbVie's Options Frenzy: What You Need to Know - AbbVie ( NYSE:ABBV )
Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 61% ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:06) / "Investors Business Daily" (by ALLISON GATLIN)
Biotech Stock Hits 2024 Low Side Effects In Rabbits Torpedo Schizophrenia Drug
Neumora Therapeutics ( NMRA ) said Monday the Food and Drug Administration put its schizophrenia drug on hold after rabbits who received it experienced convulsions. In response, the biotech stock plunged.
In Article Trend: Neutral
April 15, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 15, 2024 (05:00) / "GlobeNewswire" (by F. Hoffmann-La Roche Ltd)
[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Basel, 15 April 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) , who have received at least one ...
In Article Trend: Somewhat-Bullish
April 14, 2024 (10:15) / "Motley Fool" (by and Lee Samaha)
If You Like This High-Yield Vanguard Fund, Then You'll Love These Two Dividend Stocks
Boost your passive income in a way that's right for you.
In Article Trend: Somewhat-Bullish
April 14, 2024 (05:23) / "Motley Fool" (by Alex Carchidi)
Is AbbVie a Millionaire Maker?
Everything is going according to plan, and more growth is on the way.
In Article Trend: Somewhat-Bullish
April 13, 2024 (05:09) / "Canada Newswire"
All International Medical Approval News and Press Releases from Cision Canada
VANCOUVER, BC, April 5, 2024 /CNW/ - Asep Medical Holdings Inc. ( "Asep" or the "Company" ) ( CSE: ASEP ) ( OTCQB: SEPSF ) ( FSE: JJ8 ) is very pleased to... MONTREAL, March 25, 2024 /CNW/ - Innodem Neurosciences, a leading digital health and AI company, announced today that its ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (16:36) / "Zacks Commentary" (by Zacks Equity Research)
Alpine ( ALPN ) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
In Article Trend: Somewhat-Bullish
April 12, 2024 (14:04) / "Benzinga" (by Benzinga Insights)
Smart Money Is Betting Big In ABBV Options - AbbVie ( NYSE:ABBV )
Deep-pocketed investors have adopted a bearish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
April 11, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
In Article Trend: Neutral
April 10, 2024 (19:19) / "Benzinga" (by Vandana Singh)
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says - LENZ Therapeutics ( NASDAQ:LENZ )
Last week, LENZ Therapeutics Inc LENZ released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.
In Article Trend: Somewhat-Bullish
April 10, 2024 (16:00) / "GlobeNewswire" (by OSE Immunotherapeutics)
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer Nantes, France - April 10, 2024 - 6:00 pm CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173.
In Article Trend: Somewhat-Bullish
April 10, 2024 (15:45) / "Zacks Commentary" (by Zacks Equity Research)
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
April 10, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Nurix ( NRIX ) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
In Article Trend: Neutral
April 10, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group
AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
April 9, 2024 (20:58) / "Benzinga" (by Globe Newswire)
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DOMA, LABP, FUSN, CBNK
NEW YORK, April 09, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
In Article Trend: Somewhat-Bullish
April 9, 2024 (20:05) / "Benzinga" (by Globe Newswire)
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - Enliven Therapeutics ( NASDAQ:ELVN )
BOULDER, Colo., April 09, 2024 ( GLOBE NEWSWIRE ) -- Enliven Therapeutics, Inc. ( Enliven or the Company ) ELVN, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:44) / "Zacks Commentary" (by Sheraz Mian)
Top Stock Reports for AbbVie, Salesforce & General Electric
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) and General Electric Company (GE).
In Article Trend: Somewhat-Bullish
April 9, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree U.S. High Dividend ETF ( DHS ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (08:21) / "Motley Fool" (by Cory Renauer)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
In Article Trend: Somewhat-Bullish
April 8, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why AbbVie ( ABBV ) Fell More Than Broader Market
In the latest trading session, AbbVie (ABBV) closed at $169.80, marking a -0.12% move from the previous day.
In Article Trend: Neutral
April 8, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - Coherus BioSciences ( NASDAQ:CHRS )
- In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion - - Mechanism may enhance antitumor responses with immunotherapy - - First novel immuno-oncology ...
In Article Trend: Neutral
April 8, 2024 (11:30) / "Forbes" (by Trefis Team)
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals bellwether Johnson & Johnson ( NYSE: JNJ ) is currently a better pick over its peer AbbVie ( NYSE: ABBV ) .
In Article Trend: Somewhat-Bullish
April 6, 2024 (14:00) / "Benzinga" (by Globe Newswire)
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting - Ocular Therapeutix ( NASDAQ:OCUL )
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure ( IOP ) , statistically significant ( p<0.0001 ) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant Generally well tolerated with no impact on ...
In Article Trend: Neutral
April 6, 2024 (14:00) / "GlobeNewswire" (by Ocular Therapeutix)
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure ( IOP ) , statistically significant ( p<0.0001 ) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant ...
In Article Trend: Neutral
April 6, 2024 (10:49) / "Motley Fool" (by David Jagielski)
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks.
In Article Trend: Somewhat-Bullish
April 6, 2024 (10:37) / "Zacks Commentary" (by Zacks Equity Research)
Aldeyra ( ALDX ) Stock Rallies 43% in One Week: Here's Why
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
In Article Trend: Neutral
April 6, 2024 (01:40) / "PR Newswire" (by Halper Sadeh LLP)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA
NEW YORK, April 5, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to AstraZeneca.
In Article Trend: Somewhat-Bullish
April 5, 2024 (20:15) / "Benzinga" (by Benzinga Insights)
AbbVie Unusual Options Activity For April 05 - AbbVie ( NYSE:ABBV )
Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 25 trades. If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 68% ...
In Article Trend: Neutral
April 5, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie Inc. ( ABBV ) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:07) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.
In Article Trend: Neutral
April 4, 2024 (15:31) / "Benzinga" (by Benzinga Insights)
Smart Money Is Betting Big In ABBV Options - AbbVie ( NYSE:ABBV )
Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 80% ...
In Article Trend: Neutral
April 4, 2024 (11:17) / "PR Newswire" (by CollPlant)
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES ... PR ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (14:02) / "Benzinga" (by Vandana Singh)
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape - FibroGen ( NASDAQ:FGEN )
FibroGen Inc FGEN announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 ( also known as FOR46 ) , a potential first-in-class anti-CD46 antibody drug conjugate ( ADC ) with an MMAE-containing payload.
In Article Trend: Neutral
April 3, 2024 (04:00) / "PR Newswire"
Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024 - PR Newswire
Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024 PR ...
In Article Trend: Bullish
April 2, 2024 (20:05) / "Benzinga" (by Globe Newswire)
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery ( ASCRS ) Annual Meeting - Sight Sciences ( NASDAQ:SGHT )
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. MENLO PARK, Calif., April 02, 2024 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc.
In Article Trend: Somewhat-Bullish
April 2, 2024 (14:40) / "Benzinga" (by Globe Newswire)
Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.
In Article Trend: Neutral
April 2, 2024 (07:36) / "Motley Fool" (by Rachel Warren)
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
These stocks can deliver powerhouse portfolio growth in the years ahead.
In Article Trend: Bullish
April 2, 2024 (05:30) / "GlobeNewswire" (by OSE Immunotherapeutics)
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw AbbVie (ABBV) settling at $180.76, representing a -0.74% change from its previous close.
In Article Trend: Somewhat-Bullish
April 1, 2024 (17:17) / "Benzinga" (by Globe Newswire)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ADTH, LABP, FUSN - AdTheorent Holding ( NASDAQ:ADTH ) , Fusion Pharmaceuticals ( NASDAQ:FUSN )
NEW YORK, April 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AdTheorent Holding Company, Inc.
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:46) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers' ( BMY ) Zeposia Fails Crohn's Disease Study
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
In Article Trend: Neutral
April 1, 2024 (15:51) / "Benzinga" (by Globe Newswire)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. ( Nasdaq - ADTH ) , Agiliti, Inc. ( NYSE - AGTI ) , Landos Biopharma, Inc. ( Nasdaq - LABP ) , Fusion Pharmaceuticals Inc. ( Nasdaq - FUSN )
BALA CYNWYD, Pa., April 01, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:50) / "GlobeNewswire" (by INC.)
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
LANGHORNE, Pa., April 01, 2024 ( GLOBE NEWSWIRE ) -- NEXGEL, Inc. ( "NEXGEL" or the "Company" ) ( NASDAQ: "NXGL" ) , a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco Pharmaceuticals ETF ( PJP ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (08:30) / "Motley Fool" (by Prosper Junior Bakiny)
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations.
In Article Trend: Somewhat-Bullish
March 30, 2024 (21:15) / "Business Insider" (by Tipranks)
JEPI ETF: Turn Your Tax Return Into Monthly Dividends
It's tax time again. If you are receiving a tax return, it's the perfect opportunity to consider buying a monthly dividend ETF to jumpstart your investment portfolio.
In Article Trend: Somewhat-Bullish
March 30, 2024 (09:19) / "Motley Fool" (by Cory Renauer)
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
These advantaged businesses have what it takes to keep raising their payouts.
In Article Trend: Somewhat-Bullish
March 30, 2024 (07:00) / "Barrons" (by Bill Alpert)
A Little Biotech That Could Have Big Breakthroughs
Why Voyager Therapeutics Could Have Big Alzheimer's Breakthroughs ...
In Article Trend: Neutral
March 28, 2024 (15:17) / "Zacks Commentary" (by Zacks Investment Research)
C3.ai ( AI ) , Paradyme Extend Partnership to Deliver AI Solutions
C3.ai (AI) expands partnership agreement with Paradyme that aims at accelerating the delivery of AI solutions tailored for the U.S. Intelligence Community.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should WisdomTree U.S. High Dividend ETF ( DHS ) Be on Your Investing Radar?
Style Box ETF report for ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:00) / "GlobeNewswire" (by Zymeworks Inc.)
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
VANCOUVER, British Columbia, March 28, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:00) / "Benzinga" (by Globe Newswire)
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors - Syndax Pharmaceuticals ( NASDAQ:SNDX ) , Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, March 28, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ZYME, a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (21:58) / "Forbes" (by Katie Jennings)
InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. s a postdoctoral researcher at the Broad Institute of MIT and Harvard, Nicole Gaudelli was the co-inventor of a breakthrough in gene editing: the ability to target a single misspelling in DNA code.
In Article Trend: Somewhat-Bullish
March 27, 2024 (18:00) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie ( NYSE:ABBV )
AbbVie ABBV has outperformed the market over the past 10 years by 2.45% on an annualized basis producing an average annual return of 13.15%. Currently, AbbVie has a market capitalization of $317.49 billion.
In Article Trend: Somewhat-Bullish
March 27, 2024 (17:00) / "GlobeNewswire" (by OSE Immunotherapeutics)
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
Financial highlights ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (15:07) / "Benzinga" (by Globe Newswire)
Kuehn Law Encourages LABP, WRK, KAMN and TGAN Investors to Contact Law Firm - Landos Biopharma ( NASDAQ:LABP ) , Kaman ( NYSE:KAMN )
NEW YORK, March 27, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
In Article Trend: Bullish
March 26, 2024 (18:00) / "PR Newswire" (by Research and Markets)
Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie, AstraZeneca, Merck & Co., Novartis, Pfizer and more
Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Assessing AbbVie's Performance Against Competitors In Biotechnology Industry - AbbVie ( NYSE:ABBV )
In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating AbbVie ABBV in relation to its major competitors in the ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:03) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) to Buy Landos to Strengthen Autoimmune Portfolio
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
In Article Trend: Somewhat-Bullish
March 25, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Advances While Market Declines: Some Information for Investors
AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
In Article Trend: Somewhat-Bullish
March 25, 2024 (19:00) / "Benzinga" (by Avi Kapoor)
Nasdaq Turns Higher; Akanda Shares Plunge - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also fell, dropping, 0.12% to 5,227.95. In trading on Monday, industrials shares fell by 0.5%.
In Article Trend: Neutral
March 25, 2024 (15:54) / "Benzinga" (by Avi Kapoor)
Crude Oil Moves Higher; US New Home Sales Fall In February - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01. In trading on Monday, communication services ...
In Article Trend: Neutral
March 25, 2024 (15:45) / "Zacks Commentary" (by Zacks Equity Research)
Why AbbVie ( ABBV ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
In Article Trend: Bullish
March 25, 2024 (15:27) / "Benzinga" (by Vandana Singh)
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? - Landos Biopharma ( NASDAQ:LABP )
Monday, AbbVie Inc ABBV agreed to acquire Landos Biopharma Inc LABP for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.
In Article Trend: Somewhat-Bullish
March 25, 2024 (15:09) / "Benzinga" (by Globe Newswire)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. ( NYSE - AGTI ) , Landos Biopharma, Inc. ( Nasdaq - LABP ) , Fusion Pharmaceuticals Inc. ( Nasdaq - FUSN ) , Kinnate Biopharma Inc. ( Nasdaq - KNTE )
BALA CYNWYD, Pa., March 25, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:42) / "Benzinga" (by Avi Kapoor)
US Stocks Down; Chicago Fed National Activity Index Rises In February - Akanda ( NASDAQ:AKAN ) , AbbVie ( NYSE:ABBV )
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell 0.42% to 16,359.31. The S&P 500 also fell, dropping, 0.23% to 5,222.33.
In Article Trend: Neutral
March 25, 2024 (13:10) / "Benzinga" (by Globe Newswire)
Professional Diversity Network ( PDN ) Hosts Successful Virtual Career Fair for Women's History Month - Professional Diversity ( NASDAQ:IPDN )
CHICAGO, March 25, 2024 ( GLOBE NEWSWIRE ) -- Professional Diversity Network, Inc.
In Article Trend: Bullish
March 25, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:10) / "GlobeNewswire" (by Professional Diversity Network)
Professional Diversity Network ( PDN ) Hosts Successful Virtual Career Fair for Women's History Month
CHICAGO, March 25, 2024 ( GLOBE NEWSWIRE ) -- Professional Diversity Network, Inc. ( NASDAQ: IPDN ) ( "PDN" or the "Company" ) , a developer and operator of online and in-person networks that provide access to networking, training, educational, and employment opportunities for diverse ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search AbbVie Inc. ( ABBV ) : Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:31) / "PR Newswire" (by AbbVie)
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. ( NYSE: ABBV ) ( "AbbVie" ) and Landos Biopharma, Inc. ( NASDAQ: LABP ) ( "Landos" ) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:30) / "GlobeNewswire" (by Landos Biopharma)
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis ( UC ) - Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis ( UC ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:30) / "Benzinga" (by Globe Newswire)
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - Landos Biopharma ( NASDAQ:LABP ) , AbbVie ( NYSE:ABBV )
NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 ( GLOBE NEWSWIRE ) -- AbbVie Inc. ABBV ( "AbbVie" ) and Landos Biopharma, Inc.
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)
Council Post: What's Driving Big Pharma's Recent Market Performance?
What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 25, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors - Mirum Pharmaceuticals ( NASDAQ:MIRM ) , Century Therapeutics ( NASDAQ:IPSC )
SAN MATEO, Calif., March 25, 2024 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( ( Sagimet, NASDAQ:SGMT ) , a clinical-stage biopharmaceutical company developing novel fatty acid synthase ( FASN ) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (21:17) / "Forbes" (by James Farrell)
AbbVie's New 'Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval
The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments considered "biological missiles" because of their ability to precisely home in on cancer cells.
In Article Trend: Somewhat-Bearish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (09:38) / "Money Control"
M&A is back. Expect losers to outnumber winners
Many publicly traded companies are now sitting on sizeable cash reserves and borrowing costs appear to be stable. Buyout funds, too, are awash with cash and itching to deploy it. The worry must be that financial firepower, frustration and a fear of missing out make for ill-disciplined ...
In Article Trend: Neutral
March 21, 2024 (15:01) / "Benzinga" (by Benzinga Insights)
AbbVie Recent Insider Activity - AbbVie ( NYSE:ABBV )
Making a noteworthy insider sell on March 20, Jeffrey R. Stewart, EVP at AbbVie ABBV, is reported in the latest SEC filing. What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Stewart executed a sale of 58,949 shares of AbbVie with a total ...
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Stryker Corp. (SYK)
Cabaletta Bio, Inc. (CABA)
Kodiak Sciences Inc. (KOD)
Alpine Immune Sciences, Inc. (ALPN)
Vaccinex, Inc. (VCNX)
Esperion Therapeutics, Inc. (ESPR)
Clover Health Investments, Corp. (CLOV)
Aptorum Group Limited (APM)
Calliditas Therapeutics AB (publ) (CALT)
Cano Health, Inc. (CANO)
This website uses cookies to ensure you get the best experience on our website